Top 5 Target	Count

FtsZ(bacterial FtsZ)	3
MAP4K2 x RB1 x Syk	1
OXA1L(OXA1L mitochondrial inner membrane protein)	1
GABAA receptor(Gamma-aminobutyric acid A receptor)	1
CDT1 x MMP9 x NFKB1	1

Drugs associated with Ningbo University

Fascaplysin derivatives B14(Ningbo University)

Target

FtsZ

Mechanism

FtsZ inhibitors [+1]

Active Org.

Ningbo University

Originator Org.

Ningbo University

Active Indication

MRSA - Methicillin resistant Staphylococcus aureus infection

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

BAY 61-3606

Target

MAP4K2 x RB1 x Syk

Mechanism

MAP4K2 inhibitors [+2]

Active Org.

Columbia University Irving Medical Center [+2]

Originator Org.

St. Jude Children's Research Hospital, Inc.

Active Indication

Acute Myeloid Leukemia [+3]

Inactive Indication

Retinoblastoma

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Flavokawain A

Target

CDT1 x MMP9 x NFKB1

Mechanism

CDT1 inhibitors [+2]

Active Org.

Ningbo University [+1]

Originator Org.

Ningbo University

Active Indication

Chronic Kidney Diseases [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Ningbo University

NCT07266168

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of Ivarmacitinib as an oral glucocorticoid-sparing alternative in the treatment of polymyalgia rheumatica.

Start Date20 Jan 2026

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+9]

NCT07238959

/ Not yet recruitingNot ApplicableIIT

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. The ultimate objective is to establish the diagnostic efficacy of this approach through clinical validation, providing clinicians with a novel diagnostic tool capable of significantly reducing unnecessary prostate biopsy procedures.

Start Date01 Dec 2025

Sponsor / Collaborator

Shanghai Changzheng Hospital

[+6]

NCT07171892

/ Not yet recruitingNot ApplicableIIT

Development and Validation of a Risk Prediction Model for Ischemic Stroke in Acute Myocardial Infarction Without Comorbid Atrial Fibrillation

Study Goal:
This observational study aims to develop a tool to predict the risk of ischemic stroke(stroke caused by a blood clot) in people who survive a heart attack and do not have irregular heartbeats (atrial fibrillation) .
Key Questions:
Can we create an accurate tool using existing hospital records to identify which heart attack survivors without irregular heartbeats have the highest risk of stroke while still in the hospital? Can this tool reliably predict stroke risk at 3 months and 1 year after leaving the hospital?
About Participation:
This study will only use information from past patient medical records. If you had a heart attack and were treated at our hospital between January 1, 2014, and December 31, 2023 , and you did not have irregular heartbeats (atrial fibrillation), your anonymous health information might be included in this analysis.
No new patients are being recruited. This study analyzes existing information only.
No one will be asked to do anything new. We will not contact patients directly.
What Information Will Be Used?
Researchers will securely review past hospital records to look at information doctors usually collect during heart attack care, such as:
Your age and medical history (like previous strokes, diabetes, high blood pressure, kidney problems).
Test results (like heart pumping strength). Treatment details after your heart attack. Information on whether you had a stroke later. All personal details (like name, ID number) will be permanently removed to protect privacy.
Why This Matters:
People who survive a heart attack have a higher risk of stroke later, even without the common irregular heartbeat condition. A stroke can be life-threatening or seriously impact quality of life. This tool aims to help doctors in the future better understand a patient's individual stroke risk after a heart attack, so preventative steps can be discussed if needed.
Ethics & Safety:
Approved: This study has been reviewed and approved by our hospital's Ethics Committee to ensure it is safe and ethical.
Privacy Guaranteed: Your personal identity is protected. All data is stored securely on the hospital's protected network with strict access controls. No personal information leaves the hospital.
Researcher Note:
This tool is currently for research purposes only. It will not be used for your medical care right now.
If doctors want to use this tool in future clinical practice, a new study directly involving patients with their informed consent would be required.

Start Date21 Oct 2025

Sponsor / Collaborator

Ningbo University

100 Clinical Results associated with Ningbo University

0 Patents (Medical) associated with Ningbo University

16,579

Literatures (Medical) associated with Ningbo University

01 Apr 2026·BIOMATERIALS

Harnessing decellularized amniotic membrane properties for ureteral repair: A fibromodulin-driven approach

Article

Author: Hu, Yiwei ; Hu, Jiasheng ; Song, Baiyang ; Yang, Fang ; Rong, Hao ; Yan, Zejun ; Cheng, Yue ; Wang, Zonghuan ; Shi, Zewen ; Xu, Kailei ; Jiang, Junhui ; Zhu, Yabin ; Cao, Yuhao ; Yu, Chengling ; Fang, Li ; Yang, Xue

Ureteral reconstruction remains a significant challenge due to the risk of fibrosis and insufficient epithelial regeneration, leading to suboptimal outcomes with current surgical techniques. To address these issues, a tubular porous scaffold was developed by integrating enzymatically digested decellularized amniotic membrane (dAM) with silk fibroin and gelatin solutions, utilizing freeze-drying, compression, and cross-linking techniques. Proteomic analysis revealed that the scaffold retained key bioactive properties of dAM, promoting epithelial regeneration while inhibiting fibrosis in vitro and in vivo. Transcriptomic analyses revealed that fibromodulin (Fmod) upregulation in the scaffold modulates TGF-β1-related biological pathways, contributing to its antifibrotic effects. This study bridges biomaterial innovation with clinical needs, offering a promising strategy for scarless ureteral repair and providing a strong theoretical foundation for the translational application of dAM in regenerative medicine.

01 Feb 2026·Biomaterials advances

From 3D culture to clinical decision-making: Systematic innovations in breast cancer organoids

Review

Author: Zhao, Jiyuan ; Li, Mei ; Hu, Mingyu ; Zhou, Chenxin

Breast cancer is a malignant tumour with high heterogeneity. Traditional research models rely mainly on 2D cell culture and patient-derived tumour xenografts (PDXs). However, these models have limited use in clinical trials because of their shortcomings in mimicking the tumour microenvironment and preserving the genetic background. In recent years, organoids, emerging models capable of self-organizing to form 3D structures in vitro, have become key tools for overcoming the traditional dilemma and are promising alternatives for breast cancer research. This review integrates cutting-edge technologies such as organ-on-a-chip and CRISPR/Cas9 gene editing to summarize the multidimensional generation strategy of breast cancer organoids and discusses the clinical value of translation from diagnosis to therapy. Compared with existing studies, this review provides a systematic solution from "model generation" to "precision medicine" for breast cancer research, and the hope is that this review will pave the way for the further development of organoids.

01 Feb 2026·EVALUATION AND PROGRAM PLANNING

Causal decision-making for speed camera allocation: Methodology and an application

Article

Author: Li, Haojie ; Zhang, Yingheng

Speed enforcement cameras are implemented worldwide to regulate driving behaviours and enhance road traffic safety. Proper allocation of speed cameras is quite important. In practice, we should first identify road sites likely to experience larger crash reductions with speed cameras, but this step is commonly simplified as ranking sites based on the historical crash frequency. This paper proposes the use of causal decision-making to refine speed camera allocation rules. Within this framework, the heterogeneous treatment effects (HTEs) of speed cameras on crash frequency across different sites are first modelled by applying causal machine learning methods. Subsequently, by exploiting the trained HTE model, sites with larger predicted road safety benefits (i.e., crash reductions) will be prioritised for allocation. A UK case study is presented to demonstrate the superiority of the proposed method. Different speed camera allocation rules, including the HTE-based, historical crash-based, and random allocation, are compared with respect to the number of prevented road traffic crashes. Our empirical results indicate that a larger number of past crashes in general implies a larger safety benefit of the speed camera. Therefore, the historical crash frequency could be regarded as a useful criterion for camera site selection in the absence of additional information. Nonetheless, the HTE-based rule has been found to further enhance the allocation performance. That is, more road traffic crashes could be prevented by adopting the HTE-based rule. In future transportation research and practice, the causal decision-making framework could be applied more generally to costly resource allocation tasks.

News (Medical) associated with Ningbo University

23 Apr 2025

·www.prnewswire.com

A Breakthrough in Brain Surgery Monitoring: Guarding Lives with Raytron's Thermal Imaging Technology

YANTAI, China, April 23, 2025 /PRNewswire/ -- In high-stakes neurosurgery, gaining real-time insights into cerebral blood flow is vital yet challenging. Conventional indocyanine green (ICG) fluorescence imaging relies on contrast agents and offers limited repeatability. Now, infrared thermography cameras promise a non-contact, contrast-free, radiation-free, and non-invasive diagnostic imaging alternative, delivering continuous monitoring that enhances surgical precision and patient safety. How Infrared Thermal Imaging Empowers Medical Diagnostics Thermal imaging cameras convert subtle temperature variations from cerebral blood circulation into high-resolution thermal maps, enabling surgeons to "see" vascular flow invisible to the naked eye. This non-invasive thermal imaging technology integrates seamlessly into neurosurgical workflow, such as cerebrovascular bypass, offering continuous intraoperative monitoring without interruption. Raytron's Thermographic Imaging Camera for Clinical Application in Neurosurgery Raytron, a prominent global provider of infrared thermal imaging solutions, has developed an innovative thermal camera for medical use. In 2023, a surgical team led by Dr. Lin Jinghui at the First Affiliated Hospital of Ningbo University—a top-tier public hospital in China—deployed Raytron's proprietary ATR1280 thermal imaging camera during life-saving bypass operations for patients with moyamoya disease, a rare cerebrovascular disorder. The team conducted intraoperative infrared imaging on 21 adult patients undergoing STA-MCA (superficial temporal artery to middle cerebral artery) bypass surgery and identified several key advantages over conventional methods: Real-time, high-resolution thermal imaging camera for research Clearer visualization of anastomotic blood flow Seamless integration into the surgical workflow Greater quantitative accuracy in cerebral blood flow monitoring These benefits may support more informed decision-making and contribute to improved patient outcomes, marking a promising development in thermographic neurosurgical imaging. Raytron's Global Vision in Infrared Thermal Imaging: Raytron is a leading high-tech enterprise dedicated to the research and development of ASICs, MEMS sensors, and AI algorithms. With a portfolio of 1,200 patents and an R&D workforce comprising 48% of its over 3,000 employees, Raytron delivers advanced thermal imaging solutions in medical diagnostics, emergency response and 10 other industry sectors worldwide. Committed to advancing intelligent sensing technology solutions, Raytron aims to create incremental value for customers with technological advancements and help people discover the beauty of the world from more dimensions. For Further Information Contact us for medical-use thermal imaging solutions: Raytron Marketing Department E-mail: [email protected] Website: SOURCE Raytron Technology Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Ningbo University

100 Translational Medicine associated with Ningbo University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Flavokawain A ( CDT1 x MMP9 x NFKB1 )	Acute Myeloid Leukemia More	Preclinical
Bicuculline ( GABAA receptor )	Metabolic dysfunction-associated steatotic liver disease More	Preclinical
BAY 61-3606 ( MAP4K2 x RB1 x Syk )	Acute Myeloid Leukemia More	Preclinical
TZOA(Ningbo University)	Rhabdoviridae Infections More	Preclinical
Fascaplysin derivatives B9(Ningbo University) ( FtsZ )	MRSA - Methicillin resistant Staphylococcus aureus infection More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis